Published in Gastroenterology on July 25, 2013
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol (2015) 1.20
Polyp morphology: an interobserver evaluation for the Paris classification among international experts. Am J Gastroenterol (2014) 0.89
Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.85
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis (2015) 0.85
Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. Dig Dis Sci (2016) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis (2015) 0.80
Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med (2015) 0.79
A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Tech Coloproctol (2015) 0.78
Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res (2016) 0.77
Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol (2016) 0.77
"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol (2014) 0.76
Endoscopic Disease Activity in Inflammatory Bowel Disease. Curr Gastroenterol Rep (2015) 0.75
Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. Endosc Int Open (2017) 0.75
Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc (2016) 0.75
Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol (2016) 0.75
How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis? Dig Dis Sci (2014) 0.75
Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease. J Crohns Colitis (2017) 0.75
Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol (2017) 0.75
Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol (2017) 0.75
Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol (2017) 0.75
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother (2017) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA (2004) 23.87
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 22.34
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol (2009) 17.92
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
CONSORT statement: extension to cluster randomised trials. BMJ (2004) 16.50
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med (2010) 16.11
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med (2008) 13.87
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (2010) 12.98
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
Epidemiology and reporting characteristics of systematic reviews. PLoS Med (2007) 11.51
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust (2006) 11.40
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ (2004) 10.75
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ (2008) 9.98
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med (2010) 9.30
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med (2006) 8.25
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Comparison of registered and published primary outcomes in randomized controlled trials. JAMA (2009) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One (2009) 7.60
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (2014) 7.55
Consort 2010 statement: extension to cluster randomised trials. BMJ (2012) 7.47
Guidance for developers of health research reporting guidelines. PLoS Med (2010) 7.43
Diagnostic tests 4: likelihood ratios. BMJ (2004) 7.33
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med (2010) 6.88
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (2003) 6.61
Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet (2002) 6.61
Epidemiology and reporting of randomised trials published in PubMed journals. Lancet (2005) 6.55
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol (2013) 5.93
CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med (2008) 5.85
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (2010) 5.70
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ (2010) 5.58
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat (2007) 5.52
An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ (2009) 5.45
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ (2005) 5.36
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
The design of simulation studies in medical statistics. Stat Med (2006) 5.30
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Ghost authorship in industry-initiated randomised trials. PLoS Med (2007) 4.95
Quantification of the completeness of follow-up. Lancet (2002) 4.77
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75